Navigation Links
Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
Date:8/29/2013

LOUISVILLE, Ky. and INDIANAPOLIS, Aug. 29, 2013 /PRNewswire/ -- Humana Inc. (NYSE: HUM), one of the nation's leading health and well-being companies, and Eli Lilly and Company (NYSE: LLY), a leading, innovation-driven corporation, today announced a joint research collaboration aimed at improving the health care of their members and patients.

Under the partnership, the companies will utilize their expertise and resources to identify and analyze data and information with a focus on improving health care quality and outcomes. The partnership reflects a shared commitment by both companies to address the challenges of improving quality of care and reducing treatment costs in today's complex and changing health care environment.

"Pairing Humana's clinical expertise and rich, de-identified patient data with Lilly's history and experience across many disease states allows us to maximize the potential benefits for patient care and savings," said William Fleming, Pharm.D., President of Humana Pharmacy Solutions. "By leveraging our collective capabilities, we can work to address the critical health care needs facing our country." 

Under the terms of the multi-year agreement, the companies will conduct a range of studies related to various disease states. Study methodologies include: impact of interventions on outcomes, adherence programs, disease management and pharmacoeconomics.

The initial project is aimed at investigating patient characteristics associated with increased health care costs in people with type 2 diabetes. This retrospective analysis utilizes de-identified medical, pharmacy and laboratory claims data, in addition to research algorithms focused on exploring patient attitudes and behaviors. Future studies may use this information to identify modifiable characteristics that can be targeted with behavioral and other therapeutic interventions.

"We are pleased to partner with Humana on research that will help benefit patients facing a variety of diseases, including diabetes," said Dara Schuster, M.D., Medical Fellow, Lilly Diabetes. "Working together, we hope to provide patients with insights and guidance that will help them tailor their care to best match their individual needs."

Comprehensive Health Insights (CHI), a wholly owned subsidiary of Humana, will serve as the research engine in the collaboration.  Since 2008 CHI has successfully partnered with a wide range of industry partners to perform health economics and outcomes research using Humana's data assets.

About Humana
Humana Inc., headquartered in Louisville, Ky., is a leading health-care company that offers a wide range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. By leveraging the strengths of its core businesses, Humana believes it can better explore opportunities for existing and emerging adjacencies in health care that can further enhance wellness opportunities for the millions of people across the nation with whom the company has relationships.

More information regarding Humana is available to investors via the Investor Relations page of the company's web site at www.humana.com, including copies of:

  • Annual reports to stockholders
  • Securities and Exchange Commission filings
  • Most recent investor conference presentations
  • Quarterly earnings news releases
  • Replays of most recent earnings release conference calls
  • Calendar of events (including upcoming earnings conference call dates and times, as well as planned interaction with research analysts and institutional investors)
  • Corporate Governance information

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers — through medicines and information — for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

C-LLY

FOR MORE INFORMATION, CONTACT:

Alex Kepnes
Humana Corporate Communications 
502-580-2990
akepnes@humana.com  

Kelley Murphy
Eli Lilly and Company
317-701-4007
murphy_kelley@lilly.com   

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

(Logo: http://photos.prnewswire.com/prnh/20130829/DE70165LOGO )


'/>"/>
SOURCE Eli Lilly and Company; Humana Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Comprehensive Care Corporation Announces New Medicare Contract with Humana Health Plan of California, Inc.
2. Dr. Marschall S. Runge Elected to Lilly Board of Directors
3. Lilly Reports Second-Quarter 2013 Results
4. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
5. Lilly Disappointed in Draft Medicare Coverage Decision for Beta-Amyloid Imaging Agents
6. The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding, Haemonetics, ResMed and Eli Lilly
7. Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests
8. Lilly Declares Third-Quarter 2013 Dividend
9. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
10. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
11. Lilly Statement on Indiana Biosciences Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior ... that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will ... , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... once again host, Swirl, A Wine Tasting Event at the La Gorce Country ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Regular gym users ... themselves having to wait longer to access the treadmills. It’s a predictable trend. After ... to lose weight and get in shape by joining gyms, starting new walking or ...
Breaking Medicine News(10 mins):